United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction on Thursday, March 26th. The stock was sold at an average price of $535.81, for a total transaction of $5,090,195.00. Following the sale, the chief executive officer owned 40,513 shares of the company’s stock, valued at approximately $21,707,270.53. This trade represents a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

United Therapeutics Stock Down 1.8%

Shares of NASDAQ UTHR opened at $522.83 on Friday. The company has a market capitalization of $22.92 billion, a PE ratio of 18.74, a P/E/G ratio of 1.92 and a beta of 0.84. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $549.50. The firm has a fifty day simple moving average of $495.95 and a 200 day simple moving average of $472.65.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. During the same quarter in the prior year, the firm posted $6.19 earnings per share. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. As a group, equities analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Torren Management LLC bought a new position in United Therapeutics in the fourth quarter worth approximately $26,000. Activest Wealth Management increased its holdings in shares of United Therapeutics by 1,400.0% during the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares in the last quarter. Entrust Financial LLC acquired a new position in shares of United Therapeutics during the fourth quarter worth approximately $31,000. Wilmington Savings Fund Society FSB lifted its holdings in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares in the last quarter. Finally, Harbor Capital Advisors Inc. bought a new position in shares of United Therapeutics in the 4th quarter worth $48,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on UTHR shares. Oppenheimer raised their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Cantor Fitzgerald lifted their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Finally, TD Cowen lifted their price objective on shares of United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $549.91.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.